<code id='36D7FEC435'></code><style id='36D7FEC435'></style>
    • <acronym id='36D7FEC435'></acronym>
      <center id='36D7FEC435'><center id='36D7FEC435'><tfoot id='36D7FEC435'></tfoot></center><abbr id='36D7FEC435'><dir id='36D7FEC435'><tfoot id='36D7FEC435'></tfoot><noframes id='36D7FEC435'>

    • <optgroup id='36D7FEC435'><strike id='36D7FEC435'><sup id='36D7FEC435'></sup></strike><code id='36D7FEC435'></code></optgroup>
        1. <b id='36D7FEC435'><label id='36D7FEC435'><select id='36D7FEC435'><dt id='36D7FEC435'><span id='36D7FEC435'></span></dt></select></label></b><u id='36D7FEC435'></u>
          <i id='36D7FEC435'><strike id='36D7FEC435'><tt id='36D7FEC435'><pre id='36D7FEC435'></pre></tt></strike></i>

          Home / explore / focus

          focus


          focus

          author:hotspot    Page View:7
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In